Why Idorsia (SWX:IDIA) Is Down 14.1% After Raising CHF 65.6M in Upsized Share Offering and What’s Next

Earlier this week, Idorsia announced the completion of an upsized follow-on equity offering, raising CHF 65.6 million by issuing 16.4 million new and treasury shares at CHF 4 each through a direct listing.
This successful capital raise, supported by strong investor demand and founding shareholder participation, aims to strengthen the balance sheet and extconclude funding for commercial and pipeline growth initiatives.
We’ll explore how the infusion of capital from the equity offering could support support Idorsia’s path toward profitability and pipeline advancement.

We’ve found 19 US stocks that are forecast to pay a dividconclude yield of over 6% next year. See the full list for free.

Idorsia Investment Narrative Recap

Owning Idorsia shares means believing in the strength of its late-stage pipeline and the commercial expansion of QUVIVIQ, while accepting ongoing unprofitability and funding risks as the company strives for a turnaround. The recent CHF 65.6 million equity raise directly addresses the immediate liquidity challenge, extconcludeing Idorsia’s cash runway and supporting to mitigate the largegest short-term risk of running out of funds before major catalysts, such as the potential FDA descheduling of the DORA class, materialize. This capital infusion, while significant, doesn’t dramatically alter the timeline of regulatory or market catalysts, but it does give management more time to execute on commercial priorities.

One highly relevant announcement is the launch of QUVIVIQ in China, which broadens Idorsia’s revenue base and underpins hopes for accelerated top-line growth. Tapping into a new, large market aligns directly with investor focus on QUVIVIQ’s sales momentum as a key driver for restoring profitability in the coming years. These pipeline and commercialization advances now have further financial support thanks to the follow-on offering, potentially increasing the company’s chances of achieving its revenue tarobtains and addressing prior going concern issues.

However, investors should also be aware that even with new funding, the risk of future dilution or unmet commercial tarobtains remains if sales do not ramp up as expected…

Read the full narrative on Idorsia (it’s free!)

Idorsia’s narrative projects CHF354.7 million revenue and CHF72.6 million earnings by 2028. This requires 17.8% yearly revenue growth and a CHF205.9 million increase in earnings from CHF-133.3 million today.

Uncover how Idorsia’s forecasts yield a CHF4.00 fair value, a 5% upside to its current price.

Exploring Other Perspectives

SWX:IDIA Community Fair Values as at Oct 2025

Fair value estimates from the Simply Wall St Community range from CHF 4.00 to CHF 5.86, based on two indepconcludeent forecasts. These varied perspectives contrast with ongoing questions about QUVIVIQ’s market uptake and reveal how diverse opinions shape expectations for Idorsia’s future performance.

Explore 2 other fair value estimates on Idorsia – why the stock might be worth as much as 53% more than the current price!

Build Your Own Idorsia Narrative

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

Curious About Other Options?

Early shiftrs are already taking notice. See the stocks they’re tarobtaining before they’ve flown the coop:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only applying an unbiased methodology and our articles are not intconcludeed to be financial advice. It does not constitute a recommconcludeation to acquire or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focapplyd analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.